BioLife Solutions, Inc. Cash Flow Statement
BLFS / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
BioLife Solutions, Inc. generated $20M in operating cash flow and $11M in free cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 4.67 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$4.6M | -$20.2M | -$68.0M | -$139.8M | -$8.9M | $2.0M | -$1.7M | $4.9M | -$2.5M | -$6.9M | -$4.2M | -$3.2M | -$1.1M | -$1.7M | -$2.0M |
| Depreciation & Amortization | $2.3M | $5.2M | $7.1M | $6.8M | $4.7M | $2.0M | $718.0K | $78.0K | - | - | - | - | - | - | - |
| Operating Cash Flow | $20.1M | $8.4M | -$12.5M | -$8.5M | -$4.6M | $6.6M | $1.2M | $392.0K | $605.0K | -$4.3M | -$5.0M | -$3.2M | $146.0K | $854.9K | -$989.9K |
| Capital Expenditures | $9.5M | $3.2M | $6.4M | $10.4M | $8.4M | $2.0M | $675.0K | $41.0K | $144.0K | $143.5K | $134.0K | $589.7K | $236.7K | $1.2M | $93.5K |
| Free Cash Flow | $10.6M | $5.2M | -$18.9M | -$18.9M | -$13.0M | $4.7M | $538.0K | $351.0K | $461.0K | -$4.5M | -$5.1M | -$3.8M | -$90.7K | -$296.8K | -$1.1M |
| FCF Margin | - | - | - | - | - | - | - | - | 4.2% | -54.3% | -79.2% | -60.6% | -1.0% | -5.2% | -39.3% |